Iza Bren Improves PFS in Treated HR Positive Breast Cancer

Company SystImmune; Sichuan Biokin; Bristol Myers Squibb Event Type Phase 3 readout and publication (source-gap reconciliation) Modality Bispecific EGFR/HER3 antibody-drug conjugate Asset Izalontamab brengitecan (iza-bren, BL-B01D1) Target EGFR; HER3 (topoisomerase-I payload) Disease Area Previously treated HR-positive, HER2-negative advanced breast cancer Summary Source-gap reconciliation: an October…